Advanced by Nature
Ingenza is a biotechnology company specialising in the design, development and manufacture of diverse, high-value industrial products and therapeutic-proteins. We exploit synergies between synthetic and evolutionary biology, providing next generation microbial and mammalian manufacturing platforms.
“We value our multi-year relationship with Ingenza, who have shown great capability and flexibility to help us successfully progress our technology development programme.”
“Ingenza has an excellent and highly collaborative approach. We feel this cooperation has been more productive than the kind of relationship we could have realised with other companies, who might have attempted this work as a service contract.”
“We greatly value our interaction with Ingenza for two main reasons; accessing their deep and complementary expertise has allowed us to make progress with important projects and, secondly, their approach, team ethos and visible success was an inspiration to us when deciding to form Drochaid Research Services.”
“It has been a pleasure working with the Ingenza team. The collaborative and innovative culture shared between the Ingenza and Syngenta teams has made this collaboration a success. We are excited about the next phase of work to further evaluate the technology.”
“Ingenza’s simple diagnostic assay for confirming nasogastric (NG) tube placement is an easy-to-implement and low cost option, providing a highly specific and sensitive test with the potential to reduce the number of expensive chest X-rays.”
What makes Ingenza unique?
Dynamic teamwork forged from full integration between the in-house molecular biology, fermentation and chemistry teams, boosted by close ties to UK universities, provides the perfect skillsets to expertly guide you through your project. We can support you at any stage of development, from proof of concept to scaled-up manufacture under GMP conditions.
Combining the old and the new
Ingenza’s ethos is all about combining the best tried-and-tested traditional methods, the latest breakthroughs and technologies, and a healthy dose of experience and expertise, to bring refreshing innovation to the development of sustainable and cost-competitive biotechnology.
Ingenza supports COVID-19 response
Ingenza is applying its proprietary “visABLE” biomanufacturing platform in a recombinant bioprocess to accelerate development and testing of a COVID-19 vaccine.
The work is in collaboration with leading UK academic/innovation centres. If successful the biomanufacturing platform will facilitate rapid scale-up and production of vaccine components.
For the latest developments from Ingenza’s COVID-19 response, follow us @IngenzaLtd